Work

Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma

Year: 2022

Type: article

Abstract: In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.

Source: Kidney Cancer Journal

DOI: 10.52733/kcj20n1-rt

Authors: Nizar Tannir, Arlene Siefker-Radtke, Robert Figlin

Institutions: The University of Texas MD Anderson Cancer Center, Cedars-Sinai Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4221042783